{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-004768","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.081201+00:00","generated_at":"2026-05-23T15:29:38.560745+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Adaptimmune extends CFO Gavin Wood's departure to August 31, 2025","bullets":["Original termination date of May 31, 2025 changed to August 31, 2025 by reason of redundancy.","Severance includes 12 months base salary, discretionary pro-rata bonus for 2025, and healthcare benefits for 12 months.","Share options continue vesting until August 31, 2025; vested options exercisable for 12 months thereafter.","All other provisions of the original letter agreement and service agreement obligations survive unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-004768","json":"https://secwatch.observer/filing/0001558370-25-004768.json","markdown":"https://secwatch.observer/filing/0001558370-25-004768.md","text":"https://secwatch.observer/filing/0001558370-25-004768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000155837025004768/0001558370-25-004768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000155837025004768/adap-20250414x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:29:38.560745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2421f6deab","claim":"Gavin Wood departed as Chief Financial Officer at Adaptimmune Therapeutics PLC.","evidence_excerpt":"Mr. Wood’s employment with Adaptimmune Limited will end on August 31, 2025 (the “Revised Termination Date”) by reason of redundancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000155837025004768/0001558370-25-004768-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departure"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}